Fresenius Medical Care Corporation (NYSE:FMS) was downgraded by Zacks Investment Research from a “strong-buy” rating to a “hold” rating in a research report issued to clients and investors on Wednesday.
According to Zacks, “Fresenius Medical Care has had a disappointing run on the bourse on a year-to-date basis. The company ended the second quarter on a mixed note wherein adjusted earnings missed the Zacks Consensus Estimate, while revenues beat the same. Fresenius Medical Care reiterated its full-year guidance. We believe this is in tune with the company’s long-term objective or the ‘Growth Strategy 2020’, wherein it aims to drive revenues to $28 billion by 2020, corresponding to an average annual growth rate of 10%. A wide range of dialysis products, initiatives to attain market traction, solid international foothold, strategic acquisitions and divestments are major catalysts. Fresenius Medical Care has signed an agreement to acquire NxStage Medical for $2 billion. However, a tough regulatory environment, difficulties in boosting the profit margin in foreign legal paradigms and competition in the niche markets are major headwinds.”
Several other research analysts have also commented on FMS. Royal Bank Of Canada reaffirmed a “neutral” rating on shares of Fresenius Medical Care Corporation in a research note on Wednesday, May 3rd. DZ Bank AG reaffirmed a “neutral” rating on shares of Fresenius Medical Care Corporation in a research note on Thursday, May 11th. Nord/LB reaffirmed a “buy” rating on shares of Fresenius Medical Care Corporation in a research note on Wednesday, June 28th. UBS AG reaffirmed a “sell” rating on shares of Fresenius Medical Care Corporation in a research note on Tuesday, July 4th. Finally, BidaskClub lowered shares of Fresenius Medical Care Corporation from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 24th. One research analyst has rated the stock with a sell rating, five have given a hold rating and seven have assigned a buy rating to the company. Fresenius Medical Care Corporation presently has a consensus rating of “Hold” and an average target price of $48.67.
Shares of Fresenius Medical Care Corporation (NYSE:FMS) opened at 46.47 on Wednesday. The company has a market cap of $28.52 billion, a price-to-earnings ratio of 20.29 and a beta of 0.47. The company’s 50-day moving average is $47.37 and its 200-day moving average is $44.93. Fresenius Medical Care Corporation has a 12-month low of $38.05 and a 12-month high of $50.22.
Fresenius Medical Care Corporation (NYSE:FMS) last posted its quarterly earnings data on Tuesday, August 1st. The company reported $0.48 EPS for the quarter, missing the consensus estimate of $0.53 by $0.05. The firm had revenue of $4.47 billion for the quarter, compared to analysts’ expectations of $5.20 billion. Fresenius Medical Care Corporation had a return on equity of 11.57% and a net margin of 7.06%. The firm’s quarterly revenue was up 11.1% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.96 earnings per share. Equities research analysts predict that Fresenius Medical Care Corporation will post $2.33 earnings per share for the current year.
ILLEGAL ACTIVITY WARNING: This piece was originally published by Community Financial News and is the property of of Community Financial News. If you are viewing this piece on another publication, it was illegally copied and republished in violation of international copyright law. The legal version of this piece can be viewed at https://www.com-unik.info/2017/08/18/zacks-investment-research-downgrades-fresenius-medical-care-corporation-fms-to-hold.html.
Several hedge funds have recently modified their holdings of FMS. UBS Asset Management Americas Inc. raised its stake in shares of Fresenius Medical Care Corporation by 3.6% in the second quarter. UBS Asset Management Americas Inc. now owns 2,357 shares of the company’s stock worth $114,000 after buying an additional 81 shares in the last quarter. Pacer Advisors Inc. bought a new stake in shares of Fresenius Medical Care Corporation during the second quarter worth about $179,000. FFT Wealth Management LLC bought a new stake in shares of Fresenius Medical Care Corporation during the second quarter worth about $201,000. HPM Partners LLC bought a new stake in shares of Fresenius Medical Care Corporation during the second quarter worth about $221,000. Finally, YorkBridge Wealth Partners LLC raised its stake in shares of Fresenius Medical Care Corporation by 19.4% in the second quarter. YorkBridge Wealth Partners LLC now owns 4,613 shares of the company’s stock worth $222,000 after buying an additional 749 shares in the last quarter. 2.81% of the stock is owned by hedge funds and other institutional investors.
Fresenius Medical Care Corporation Company Profile
Fresenius Medical Care AG & Co KGaA is a kidney dialysis company. The Company provides dialysis care and related services to persons suffering from end-stage renal disease (ESRD), as well as other healthcare services. The Company’s segments include North America Segment, the Europe, Middle East and Africa (EMEA) Segment, the Asia-Pacific Segment and the Latin America Segment.
What are top analysts saying about Fresenius Medical Care Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Fresenius Medical Care Corporation and related companies.